Routine inducement grants for new hires — no material impact on stock. Monitor for any future updates on pipeline catalysts (obexelimab, orelabrutinib) or activist developments.
Price Chart
Executive Summary
Zenas BioPharma granted inducement stock options and RSUs to new hires under Nasdaq Rule 5635(c)(4). The grants are routine compensation for new employees and do not signal any change in business operations or financial performance.
Key Facts
- Granted non-qualified stock options for 53,700 shares at $31.93 exercise price, vesting over 4 years.
- Granted 98,900 RSUs vesting in equal annual installments over 4 years starting Sept. 2027.
- Grants made under the 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
- Stock options have a 10-year term; exercise price equals the closing price on the grant date.
Financial Impact
Minimal — 53,700 options + 98,900 RSUs represent less than 1% of outstanding shares (approximately 0.3% based on typical float).
Risk Factors
- No financial or pipeline updates provided in this filing.
- Inducement grants are standard and do not indicate operational changes.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.63 (+3.44%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.63 (+9.82%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.63 (−16.40%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.63 (−15.12%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.63 (−13.41%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.63 (+48.87%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.63 (+54.88%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.63 (+38.64%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.63 (+38.64%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.63 (+38.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers